Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Opioid-Related Disorders
Open-data reference.
53 US clinical trials · 8 currently recruiting
Active & Recent Trials
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
University of Pittsburgh
NCT06810076
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
University of Utah
NCT06387290
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
University of Arkansas
NCT05336188
fMRI and Opioid Abstinence
Yale University
NCT06651333
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
National Institute on Drug Abuse (NIDA)
NCT03745339
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
VA Office of Research and Development
NCT06454903
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Indiana University
NCT05603702
Psilocybin in Cancer Pain Study
Yvan Beaussant, MD, MSci
NCT06001749
More Individualized Care: Assessment and Recovery Through Engagement
Kaiser Permanente
NCT05122676
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
April M Young
NCT05657106
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
Ohio University
NCT05505227
Healthy Opioid Prescription Engagement
Jerry Cochran
NCT05141266
OUD Smartphone Services
Western Michigan University
NCT06134882
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Yih-Ing Hser
NCT06023459
Tau PET Imaging in Opioid Use Disorder
University of Pennsylvania
NCT05651516
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
West Virginia University
NCT03950492
Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
University of Washington
NCT03932799
Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients
Weill Medical College of Cornell University
NCT03377855
The Kentucky Viral Hepatitis Treatment Study
Jennifer Havens
NCT03949764
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Orexo AB
NCT01848054
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
San Francisco Department of Public Health
NCT03838510
Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR
Chestnut Health Systems
NCT05380440
Safety & Prevention Outcomes Study
University of Michigan
NCT01894087
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
National Institute on Drug Abuse (NIDA)
NCT00000318
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
National Institute on Drug Abuse (NIDA)
NCT00218127
Medication Treatment for Opioid Use Disorder in Expectant Mothers
T. John Winhusen, PhD
NCT03918850
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
New York State Psychiatric Institute
NCT00061087
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
T. John Winhusen, PhD
NCT03911466
Substance Use Treatment and Recovery Team (START)
RAND
NCT04314648
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
T. John Winhusen, PhD
NCT03911739
Opioid Dependence Treatment Therapies in Pregnancy
University of Pittsburgh
NCT03098407
Transforming Opioid Prescribing in Primary Care
Boston Medical Center
NCT01909076
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
Roxane Laboratories
NCT00992095
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Acura Pharmaceuticals
NCT01759446
Study of Computer-Based Treatment for Drug Dependence
Yale University
NCT01315184
Buprenorphine Group Medical Visits in Primary Care
Montefiore Medical Center
NCT02526212
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
Duke University
NCT02978417
Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse
Pain Therapeutics
NCT00734461
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
University of Vermont
NCT01004393
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
University of Chicago
NCT00000250
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
University of Chicago
NCT00000256
A Laboratory Model for Heroin Abuse Medications - 8
New York State Psychiatric Institute
NCT00000273
Alternate-Day Buprenorphine Administration. Phase VII - 8
National Institute on Drug Abuse (NIDA)
NCT00000226
Alternate Day Buprenorphine Administration, Phase IX - 14
University of Vermont
NCT00000232
Buprenorphine Dose Alteration Study - 1
University of Vermont
NCT00000219
Buprenorphine and Naloxone Combination Study - 10
National Institute on Drug Abuse (NIDA)
NCT00015288
Buprenorphine Detoxification - BBDVI - 19
National Institute on Drug Abuse (NIDA)
NCT00000237
Feasibility Study of Take-Home LAAM Medication - 3
University of California, Los Angeles
NCT00000300
Buprenorphine Maintenance for Opiate Dependence - 6
National Institute on Drug Abuse (NIDA)
NCT00000357
Comparison of Buprenorphine and Methadone - 3
National Institute on Drug Abuse (NIDA)
NCT00000334
Buprenorphine Pharmacology Related to Addiction Treatment - 18
National Institute on Drug Abuse (NIDA)
NCT00000236
Buprenorphine Detox With Two Types of Treatment. BBD II - 11
University of Vermont
NCT00000229
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
National Institute on Drug Abuse (NIDA)
NCT00000358
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 5 |
| Phase 2 | 18 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Opioid-Related Disorders Trial Landscape
ClinicalTrials.gov lists 53 US studies indexed under Opioid-Related Disorders, and 8 of those are currently open to recruitment — roughly 15% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Opioid-Related Disorders shows 8 late-stage studies (Phase 3 and Phase 4 combined) alongside 23 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Opioid-Related Disorders is led by National Institute on Drug Abuse (NIDA) with 10 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 53 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Opioid-Related Disorders?
PlainTrial tracks 53 US clinical trials for Opioid-Related Disorders, of which 8 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Opioid-Related Disorders?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.